Skip to content
Screener

Novavax NVAX Q1 2026 earnings

Reported May 6, 2026 · Before market open

Revenue$139.5MBeat by $59.7M
EPS-$0.06Beat by $0.19
Revenue estimate$79.8M
EPS estimate-$0.25

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$72.7M
EPS estimate-$0.37

Financials

Q1 2026

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.33B+28.6%
Enterprise value$1.39B+68.6%
P/S2.2×+1.4×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp

Returns & leverage

See full
Current ratio2.5×+0.4×

Segments

By geography

See full
Rest of the world$23.3M-46.5%
Europe$20.1M+149%

By segment

See full
Reportable Segment$139.5M-79.1%

By product

See full
Royalties$3.5M—

FAQ

When did Novavax report Q1 2026 earnings?
Novavax (NVAX) reported Q1 2026 earnings on May 6, 2026 before market open.
What were Novavax's Q1 2026 revenue and EPS?
Novavax reported revenue of $139.5M and eps of $-0.06 for Q1 2026.
Did Novavax beat estimates in Q1 2026?
Revenue beat the consensus estimate of $79.8M by $59.7M. EPS beat the consensus estimate of $-0.25 by $0.19.
How did Novavax's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 79.1% from $666.7M a year earlier.
Where can I find Novavax's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-030924) and the 10-Q periodic report (0001628280-26-030917) directly on SEC EDGAR. The filing index links above go to sec.gov.